Navigation Links
WaferGen Announces Signing of Two Private Placements
Date:5/19/2008

FREMONT, Calif., May 19 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, today announced the signing of two separate private placements. The details of the financings, which have not yet closed, are as follow:

-- WaferGen has agreed to sell shares of the company's common stock and

warrants to certain funds for which Brencourt Advisors is the

investment manager and to certain other existing investors in a private

placement for total proceeds of approximately $3.6 million. Under the

terms of the agreement, WaferGen will sell 1,585,550 shares of common

stock at a price of $2.25 per share, with 40% warrant coverage at an

exercise price of $3.00 per share. The warrants have a five-year term

and standard broad-based weighted-average anti-dilution protection.

The financing is expected to close in the next couple of days.

Proceeds from this financing will be used for general corporate

purposes including the continued advancement of the company's

SmartChip(TM) Real-Time PCR System, as well as the expansion of the

company's global commercialization campaign for its SmartSlide(TM)

Micro-Incubation System.

-- WaferGen has agreed to sell redeemable convertible preferred shares in

the company's wholly owned Malaysian subsidiary, WaferGen Biosystems

(M) Sdn. Bhd., in a private placement to Malaysian Technology

Development Corporation Sdn. Bhd. (MTDC), a leading venture capital and

development firm in Malaysia. Under the terms of the agreement,

WaferGen has agreed to sell 444,444 redeemable convertible preferred

shares in the subsidiary for gross proceeds of $1.0 million. WaferGen

will sell an additional 444,444 redeemable convertible preferred shares

in the subsidiary for gross proceeds of an additional $1.0 million if

the subsidiary achieves certain agreed-upon milestones. The

convertible preferred shares are exchangeable into such number of

shares of common stock of WaferGen equal to the aggregate investment

made in the subsidiary divided by US$2.25 per share. The Malaysian

financing is subject to certain closing conditions. There can be no

assurance that the closing of the financing will occur in a timely

manner, if at all.

Proceeds from this financing will be used to manufacture and

commercialize the company's SmartChip(TM) Real-Time PCR System.

"We are very pleased to announce these financings and to partner with both the MTDC and key U.S. institutional investors, to support and advance our product development and worldwide commercialization efforts at WaferGen," stated Alnoor Shivji, WaferGen's chairman and chief executive officer. "MTDC is a strong and experienced investor and partner in Malaysia and this new relationship will provide tremendous strategic advantage as we work to initiate our development and commercialization work for the SmartChip system in Malaysia. In the U.S., we are thrilled to have the new support of Brencourt Advisors, a successful and experienced group that will undoubtedly offer WaferGen critical guidance as we move the company through the development stage and toward broader commercialization."

This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any of securities referenced herein, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The securities being offered have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933, as amended.

About WaferGen

WaferGen Biosystems Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping, cell biology and stem cell research for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip(TM) is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform and promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. WaferGen currently markets its SmartSlide(TM) family of products to companies and organizations involved in stem cell and cell biology research. SmartSlide(TM), which was launched in 2006, represents the first fluidics integrated micro-incubators enabling cell biology and stem cell research. Representative SmartSlide(TM) customers include Harvard University, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, Abbott Labs, and the National Institutes of Health (NIH).

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements include statements relating to the anticipated closing of the company's two financings and other statements that are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. For such statements, the company claims the protection of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) conditions to the closing of the financings may not be satisfied; (ii) the financings may involve unexpected costs, unexpected liabilities or unexpected delays; (iii) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (iv) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (v) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (vi) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward- looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Quarterly Report on Form 10-Q filed with the SEC on November 13, 2007. Investors and security holders are urged to read this document free of charge on the SEC's web site at http://www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact:

Vida Communication (on behalf of WaferGen)

Stephanie Diaz (investors) Tim Brons (media)

415-675-7400 415-675-7402

sdiaz@vidacommunication.com tbrons@vidacommunication.com


'/>"/>
SOURCE WaferGen Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference
2. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
3. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
4. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
5. WaferGen Announces Management Team Promotions
6. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
7. WaferGen to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
8. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
9. CorVel Corporation Announces Earnings Release Webcast
10. Boston Scientific Announces FDA Approval of New Heart Failure Lead
11. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... ... technology at the Spring 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments ... heavy metals, and more. Expo attendees can stop by booth 1021 to learn ...
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that Martine Rothblatt ... Therapeutics will provide an overview and update on the ... Annual Health Care Conference. The presentation will ... a.m. Eastern Time, and can be accessed via a ...
(Date:4/27/2016)... ... 27, 2016 , ... A compact PET scanner called NuPET™ ... (Magnetic Resonance Imaging) in existing third-party MRI systems. PET and MRI are complementary ... subjects. Simultaneous PET/MRI imaging offers a solution to many challenges that face researchers ...
(Date:4/27/2016)... 27, 2016 ReportsnReports.com adds ... specific focus on US, EU, China ... to the healthcare business intelligence collection of its ... Complete report on the Flow Cytometry market spread ... with 282 tables and figures is now available ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):